Published in Ann Pharmacother on May 11, 2004
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50
Etanercept as monotherapy in patients with psoriasis. N Engl J Med (2003) 4.57
p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev (2005) 3.88
Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest (2005) 3.22
Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J Cell Biol (2005) 3.14
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol (2004) 2.96
Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev (2010) 2.68
Fusion of cells by flipped SNAREs. Science (2003) 2.60
Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med (2002) 2.37
Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol (2009) 2.21
c-Jun N-terminal kinase activation mediates downregulation of connexin43 in cardiomyocytes. Circ Res (2002) 2.11
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol (2004) 2.07
Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem (2003) 1.95
Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest (2009) 1.83
Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat (2009) 1.80
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol (2009) 1.76
Myocardin induces cardiomyocyte hypertrophy. Circ Res (2006) 1.74
Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. J Mol Cell Cardiol (2009) 1.72
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol (2002) 1.71
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab (2007) 1.70
Divergent mitochondrial biogenesis responses in human cardiomyopathy. Circulation (2013) 1.69
Junctophilin type 2 is associated with caveolin-3 and is down-regulated in the hypertrophic and dilated cardiomyopathies. Biochem Biophys Res Commun (2004) 1.69
Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol (2010) 1.65
The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest (2003) 1.61
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
Sequence characteristics of functional siRNAs. RNA (2005) 1.59
FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol (2006) 1.56
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol (2006) 1.54
Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ Res (2009) 1.52
Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition. Am J Physiol Heart Circ Physiol (2004) 1.51
New viral vaccines for dermatologic disease. J Am Acad Dermatol (2008) 1.50
Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. Cancer Biol Ther (2004) 1.49
A novel mitochondrial matrix serine/threonine protein phosphatase regulates the mitochondria permeability transition pore and is essential for cellular survival and development. Genes Dev (2007) 1.49
p38-MAPK induced dephosphorylation of alpha-tropomyosin is associated with depression of myocardial sarcomeric tension and ATPase activity. Circ Res (2007) 1.48
Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res (2005) 1.48
Atrial chamber-specific expression of sarcolipin is regulated during development and hypertrophic remodeling. J Biol Chem (2003) 1.44
Hybrid mouse diversity panel: a panel of inbred mouse strains suitable for analysis of complex genetic traits. Mamm Genome (2012) 1.43
Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction. J Mol Cell Cardiol (2005) 1.42
Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42
Phosphoproteome analysis reveals regulatory sites in major pathways of cardiac mitochondria. Mol Cell Proteomics (2010) 1.41
Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ Res (2011) 1.41
Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol (2005) 1.41
Macrocephalic mental retardation associated with a novel C-terminal MECP2 frameshift deletion. Eur J Pediatr (2004) 1.39
Parvovirus B19-associated systemic lupus erythematosus: clinical mimicry or autoimmune induction? J Rheumatol (2010) 1.39
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol (2004) 1.36
Protein phosphatase 2Cm is a critical regulator of branched-chain amino acid catabolism in mice and cultured cells. J Clin Invest (2009) 1.36
Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. Circ Res (2010) 1.34
p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res (2002) 1.34
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol (2004) 1.33
Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. J Clin Invest (2010) 1.28
TAB-1 modulates intracellular localization of p38 MAP kinase and downstream signaling. J Biol Chem (2005) 1.28
An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet (2010) 1.26
p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation (2005) 1.26
Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. J Clin Invest (2011) 1.26
Connections between psoriasis and Crohn's disease. J Am Acad Dermatol (2003) 1.26
Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury. J Mol Cell Cardiol (2008) 1.25
Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. Trends Cardiovasc Med (2004) 1.23
The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol (2010) 1.22
Endothelial deletion of murine Jag1 leads to valve calcification and congenital heart defects associated with Alagille syndrome. Development (2012) 1.21
Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit? Cardiovasc Res (2011) 1.18
Inhibition of p38 alpha MAPK rescues cardiomyopathy induced by overexpressed beta 2-adrenergic receptor, but not beta 1-adrenergic receptor. J Clin Invest (2007) 1.17
Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol (2010) 1.16
Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol (2009) 1.15
Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol (2006) 1.14
Klf15 orchestrates circadian nitrogen homeostasis. Cell Metab (2012) 1.14
Human immunodeficiency virus type 1 hnRNP A/B-dependent exonic splicing silencer ESSV antagonizes binding of U2AF65 to viral polypyrimidine tracts. Mol Cell Biol (2003) 1.14
Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol (2004) 1.14
Modulation of in vivo cardiac function by myocyte-specific nitric oxide synthase-3. Circ Res (2004) 1.13
"Good enough solutions" and the genetics of complex diseases. Circ Res (2012) 1.13
MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res (2010) 1.12
Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol (2009) 1.12
Overexpression of bone morphogenetic protein 10 in myocardium disrupts cardiac postnatal hypertrophic growth. J Biol Chem (2006) 1.12
Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet (2012) 1.12
Imaging seizure activity: a combined EEG/EMG-fMRI study in reading epilepsy. Epilepsia (2008) 1.12
TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol (2002) 1.11
Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. Am J Physiol Heart Circ Physiol (2003) 1.11
Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit (2004) 1.10
Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med (2008) 1.10
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol (2007) 1.10
Functional diversity of mammalian type 2C protein phosphatase isoforms: new tales from an old family. Clin Exp Pharmacol Physiol (2008) 1.09
Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin. Hum Mol Genet (2010) 1.09
Paraneoplastic dermatoses associated with gynecologic and breast malignancies. Obstet Gynecol Surv (2010) 1.09
Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte. Circ Res (2010) 1.08
Robust adenoviral and adeno-associated viral gene transfer to the in vivo murine heart: application to study of phospholamban physiology. Circulation (2003) 1.08
Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial. Arch Dermatol (2002) 1.07
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet (2007) 1.07
Targeted activation of c-Jun N-terminal kinase in vivo induces restrictive cardiomyopathy and conduction defects. J Biol Chem (2004) 1.07
Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination. FASEB J (2003) 1.06
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol (2011) 1.06
Consensus guidelines for the management of plaque psoriasis. Arch Dermatol (2012) 1.06
Synthesis and target identification of hymenialdisine analogs. Chem Biol (2004) 1.05
Systems-based approaches to cardiovascular disease. Nat Rev Cardiol (2012) 1.04